Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

DelveInsight's,“ PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025 ” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell ...

China NMPA approves Akeso's PD-1/CTLA-4 bispecific antibody cadonilimab for first-line treatment of cervical cancer: Hong Kong Friday, June 6, 2025, 12:00 Hrs [IST] Akeso, Inc., a ...

an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies in early clinical development. Other candidates are also coming through development, including Ottimo Pharma ...

Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.

We have previously identified PD-L1 as a ligand for PD-1 13 ... IL-2, IL-4, IFN-γ and IL-10 were analyzed with monoclonal antibodies and recombinant cytokine standards from PharMingen.